<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01994460</url>
  </required_header>
  <id_info>
    <org_study_id>J-1310-026-523</org_study_id>
    <nct_id>NCT01994460</nct_id>
  </id_info>
  <brief_title>Linezolid Instead of Ethambutol in Treatment of Drug-susceptible Tuberculosis</brief_title>
  <official_title>Substitution of Ethambutol With Linezolid During the Intensive Phase of Treatment of Pulmonary Tuberculosis: A Prospective, Multicenter, Randomized, Open-label Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health &amp; Welfare, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SMG-SNU Boramae Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current standard short-course treatment for pulmonary TB requires 6 months to complete.
      This long duration of treatment increases the likelihood of side effects while decreasing
      patients' adherence to anti-TB drugs. Linezolid showed considerable efficacy against
      refractory multidrug-resistant TB. Considering the marked anti-TB effects of linezolid as
      well as the possible adverse effects of its long-term use, it is rational to use linezolid
      instead of ethambutol for the first 4 weeks of treatment for drug-susceptible pulmonary TB.
      Through randomized controlled trial, the investigators will evaluate the hypothesis that the
      use of linezolid instead of ethambutol will increase the sputum culture conversion rate by
      15% after 2 months of treatment. Patients with TB without resistance to rifampicin will be
      randomized to the following three arms at a 1:1:1 ratio: Arma 1 (control arm), Arm 2
      (linezolid for 2 weeks instead of ethambutol), Arm 3 (linezolid for 4 weeks instead of
      ethambutol)Primary outcome will be sputum culture conversion rate after 2 months of treatment
      (liquid media).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sputum culture conversion rate on liquid media</measure>
    <time_frame>after 2 months of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sputum culture conversion rate on solid media</measure>
    <time_frame>after 2 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to sputum culture conversion (liquid and solid media)</measure>
    <time_frame>During 6 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cure rate</measure>
    <time_frame>After 6 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment success rate</measure>
    <time_frame>after 6 months of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">429</enrollment>
  <condition>Pulmonary Tuberculosis Without Resistance to Rifampicin</condition>
  <arm_group>
    <arm_group_label>Arm 1 (control arm)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard treatment for drug-sensitive pulmonary TB using isoniazid (6 months), rifampicin (6 months), pyrazinamide (2 months), and ethambutol (2 months)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 (experimental arm 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Isoniazid (6 months), rifampicin (6 months), pyrazinamide (2 months), and linezolid (600 mg/day, 2 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3 (experimental arm 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Isoniazid (6 months), rifampicin (6 months), pyrazinamide (2 months), and linezolid (600 mg/day, 4 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linezolid</intervention_name>
    <arm_group_label>Arm 2 (experimental arm 1)</arm_group_label>
    <arm_group_label>Arm 3 (experimental arm 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethambutol</intervention_name>
    <arm_group_label>Arm 1 (control arm)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females aged from 20 to 80 years (20- and 80-year-old patients can
             participate).

          -  Documented sputum Xpert MTB/RIF assay-positive pulmonary TB at screening.

          -  On current TB therapy (if any) for ≤14 days at the time of enrollment.

        Exclusion Criteria:

          -  Patients with HIV/AIDS.

          -  Females of childbearing potential, who are pregnant, breastfeeding, or unwilling to
             avoid pregnancy.

          -  Any of the following:

             i.Absolute neutrophil count of &lt;2000 cells/mL. ii.White blood cell count (WBC) of
             &lt;3000/μL. iii.Hemoglobin concentration of &lt;7.0 g/dL. iv.Serum creatinine level of &gt;2.0
             mg/dL. v.Aspartate aminotransferase (AST or SGOT) of &gt;100 IU/L. vi.Alanine
             aminotransferase (ALT or SGPT) of &gt;100 IU/L. vii.Total bilirubin level of &gt;2.0 mg/dL.
             viii.History of optic neuritis or peripheral neuropathy. ix.Other significant
             laboratory abnormalities (i.e., absolute neutrophil count, creatinine level).

             x.The need for ongoing therapy with SSRIs, tricyclic antidepressants, serotonin 5-HT1
             receptor agonists (triptans), meperidine, buspirone, monoamine oxidase inhibitors
             (MAOIs), sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g.,
             epinephrine, norepinephrine), or dopaminergic agents (e.g., dopamine, dobutamine).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae-Joon Yim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jae-Joon Yim, MD</last_name>
    <phone>82-2-2072-2059</phone>
    <email>yimjj@snu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Kyunggi</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jong Sun Park, MD</last_name>
      <phone>031-787-7054</phone>
      <email>jspark.im@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jong Sun Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>100-799</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ji Yeon Lee, MD</last_name>
      <phone>82222607284</phone>
      <email>jedidiah125@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ji Yeon Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SMG-SNU Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>156-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deog Kyeom Kim, MD</last_name>
      <phone>02-870-2228</phone>
      <email>kimdkmd@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Deog Kyeom Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2013</study_first_submitted>
  <study_first_submitted_qc>November 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2013</study_first_posted>
  <last_update_submitted>December 27, 2014</last_update_submitted>
  <last_update_submitted_qc>December 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jae-Joon Yim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Tuberculosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linezolid</mesh_term>
    <mesh_term>Ethambutol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

